Showing 301-310 of 5059 results for "".
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- TSLMS Presents the 10th Annual SCALE Meetinghttps://practicaldermatology.com/news/20140728-tslms_presents_the_10th_annual_scale_meeting/2459157/The Omni Hotel in Nashville, TN will host the 10th annual SCALE meeting March 6-8, 2015. Sponsored by the Tennessee Society for Laser Medicine & Surgery, the Symposium for Cosmetic Advances and Laser Education is now accepting applications for exhibitors and accepting registrations.
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- More Than 1,000 Ulthera Systems Sold Worldwidehttps://practicaldermatology.com/news/20120725-more_than_1000_ulthera_systems_sold_worldwide/2459764/Ulthera, Inc. has sold more than 1,000 Ulthera Systems globally, with more than 100,000 treatments performed using the System. Ultherapy is a non-invasive face and neck treatment to help lift and tighten. In the first half of 2012, the company rep